Clinical trial Recruiting at 1 site Interventional Ages 55 and up

Non-invasive brain stimulation to improve cognitive and motor function in dementia patients

Official title: Multifocal Transcranial Current Stimulation for Cognitive and Motor Dysfunction in Dementia

Run by Hebrew SeniorLife · NCT05661084 · Data updated 2026-11-12

This study is testing whether a new brain stimulation treatment at home can help improve memory and movement in older adults with mild cognitive impairment or mild dementia.

Quick facts

Study typeInterventional
Ages55 Years and up
SexAll
Enrollment144 (estimated)
SponsorHebrew SeniorLife
Academic / other
Locations1 site (Boston, Massachusetts)
StatusRecruiting
StartedJanuary 24, 2023
Main results expectedDecember 31, 2026
Study endsAugust 31, 2027
Registry record updatedJanuary 12, 2026
Trial IDNCT05661084 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are older adults with mild cognitive impairment or mild dementia who can provide informed consent and have a caregiver willing to assist.

Probably not a fit

Patients with major psychiatric co-morbidities or severe cognitive impairment may not benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project examines the effectiveness of a caregiver-led, home-based brain stimulation intervention using transcranial alternating current stimulation (tACS) and transcranial direct current stimulation (tDCS) to enhance memory, mobility, and executive function in older adults with mild cognitive impairment or mild dementia. The study will involve 144 participants who will be randomized into four groups receiving different combinations of active and sham stimulation. Each participant will undergo 20 sessions of stimulation over four weeks, with assessments conducted before, immediately after, and at three and six months post-intervention. The goal is to determine if combining tACS and tDCS can optimize functional outcomes for these patients.

Why it matters

Potential benefit: If successful, this intervention could significantly enhance cognitive and motor functions in patients with mild dementia, improving their quality of life.

How similar studies have gone: Other studies have shown promise with similar brain stimulation techniques, suggesting potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Participants (Ps)

* willing and capable to give informed consent for the participation in the study after it has been thoroughly explained
* able and willing to comply with all study requirements
* an informed consent form was signed
* able to read, write, and communicate in English

Caregiver/Administrators (As)

* at least 18 years of age
* able to read, write, and communicate in English
* self-reported computer proficiency and willingness to learn how to use tES as defined by "yes" answers to the questions "Do you feel comfortable using a computer?" and "Are you willing to be the primary caregiver for a participant and learn how to administer tES?"
* stated availability during weekdays throughout the study period to administer tES to the Ps

Exclusion Criteria:

Participants (Ps)

* major psychiatric co-morbidity including major depressive disorder, schizophrenia or psychosis
* blindness or other disabilities that prevent task performance
* contraindications to tES, as recorded on a standardized screening questionnaire, which include a reported seizure within the past two years, use of neuroactive drugs, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, etc.)
* the presence of any active dermatological condition, such as eczema, on the scalp a score of 18 or less on the Montreal Cognitive Assessment (MoCA) during the in-person screen
* an inability to understand study procedures following review of the Informed Consent form
* Understanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the "Assessment of Protocol Understanding" form. Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator

Caregiver/Administrators (As)

* mild cognitive impairment defined by a MoCA score ≤26 during the in-person screen
* insufficient understanding of study procedures following review of the Informed Consent form
* Understanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the "Assessment of Protocol Understanding" form. Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator.
* poor eyesight, severe arthritis in the hands, pain, deformity or other condition that interferes with successful administration of tES

Where it's running

  • Hinda and Arthur Marcus Institute for Aging Research
    Boston, Massachusetts, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.